May 7, 2018 / 12:22 PM / 5 months ago

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

May 7 (Reuters) - Redhill Biopharma Ltd:

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

* REDHILL BIOPHARMA - TOP-LINE RESULTS FROM PHASE III STUDY WITH RHB-104 FOR CROHN'S DISEASE EXPECTED TO BE ANNOUNCED IN APPROXIMATELY THREE MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below